|
Product Disclosures
Reflecting standard oncology practice, which often requires the off-label or investigational use of some products, this educational activity does not include information about many drugs. All faculty participating in continuing education activities are expected to disclose the approved or investigational status (related to the subject matter of this virtual lecture—CRC) of all products and devices under discussion. This information, as of the time of publication, is summarized briefly in the table below. In addition, primary references and full prescribing information should be consulted for complete information. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgement and accepted standards of care.
|
Generic Name |
Brand Name |
FDA Approved for CRC |
FDA Approved for Other Cancers |
FDA Approved for Other Uses |
|
Bevacizumab |
Avastin |
√ |
√ |
|
|
Capecitabine |
Xeloda |
√ |
√ |
|
|
|
Erbitux |
√ |
√ |
|
|
|
Platinol |
|
√ |
|
|
|
Adriamycin |
|
√ |
|
|
|
Adrucil |
√ |
√ |
|
|
|
Camptosar |
√ |
|
|
|
|
Leucovorin calcium |
√ |
√ |
√ |
|
|
Mutamycin |
|
√ |
|
|
|
Eloxatin |
√ |
|
|
|
|
Vectibix |
√ |
|
|
Drug Facts and Comparisons. St Louis, Mo: Facts & Comparisons; 2007.
|